BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37146302)

  • 1. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
    Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma.
    Cornelison R; Marrah L; Fierti A; Piczak C; Glowczyk M; Tajammal A; Lynch S; Li H
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
    Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
    Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
    J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
    Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
    Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
    Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
    Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
    Nguyen TH; Barr FG
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30373318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
    Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).
    Picchione F; Pritchard C; Lagutina I; Janke L; Grosveld GC
    Carcinogenesis; 2011 Apr; 32(4):452-61. PubMed ID: 21177767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative correlation of single-cell
    Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.